Study on building index system of risk assessment of post-marketing Chinese patent medicine based on AHP-fuzzy neural network.
- Author:
Yuanyuan LI
1
;
Yanming XIE
;
Yingkun FU
Author Information
1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. chibjyy@163.com
- Publication Type:Journal Article
- MeSH:
Drug-Related Side Effects and Adverse Reactions;
Fuzzy Logic;
Humans;
Neural Networks (Computer);
Nonprescription Drugs;
adverse effects;
Product Surveillance, Postmarketing;
Risk Assessment
- From:
China Journal of Chinese Materia Medica
2011;36(20):2828-2830
- CountryChina
- Language:Chinese
-
Abstract:
Currently massive researches have been launched about the safety, efficiency and economy of post-marketing Chinese patent medicine (CPM) proprietary Chinese medicine, but it was lack of a comprehensive interpretation. Establishing the risk evaluation index system and risk assessment model of CPM is the key to solve drug safety problems and protect people's health. The clinical risk factors of CPM exist similarities with the Western medicine, can draw lessons from foreign experience, but also have itself multi-factor multivariate multi-level complex features. Drug safety risk assessment for the uncertainty and complexity, using analytic hierarchy process (AHP) to empower the index weights, AHP-based fuzzy neural network to build post-marketing CPM risk evaluation index system and risk assessment model and constantly improving the application of traditional Chinese medicine characteristic is accord with the road and feasible beneficial exploration.
